These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 6224678)
1. In vitro antibacterial activity of norfloxacin compared with eight other antimicrobial agents. Body BA; Fromtling RA; Shadomy S; Shadomy HJ Eur J Clin Microbiol; 1983 Jun; 2(3):230-4. PubMed ID: 6224678 [TBL] [Abstract][Full Text] [Related]
2. In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim. Neu HC; Labthavikul P Antimicrob Agents Chemother; 1982 Jul; 22(1):23-7. PubMed ID: 6214995 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of pefloxacin compared to that of quinolones and other antimicrobial agents. Neu HC; Chin NX; Labthavikul P; Saha G Chemioterapia; 1984 Aug; 3(4):235-41. PubMed ID: 6241847 [TBL] [Abstract][Full Text] [Related]
5. Study of the in vitro activity of norfloxacin and other drugs on amoxicillin-resistant uropathogenic isolates. Piccolomini R; Allocati N; Catamo G Chemioterapia; 1984 Jun; 3(3):167-72. PubMed ID: 6241505 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of norfloxacin in urine compared to that of cinnoxacin, nalidixic acid and pipemidic acid. Shah PM; Ottrad M; Stille W Eur J Clin Microbiol; 1983 Jun; 2(3):272-4. PubMed ID: 6224688 [No Abstract] [Full Text] [Related]
7. In-vitro activity of norfloxacin against Enterobacteriaceae and Pseudomonas aeruginosa. García-Rodríguez JA; Gómez-García AC; Rodrigo N J Antimicrob Chemother; 1984 Aug; 14(2):192-3. PubMed ID: 6238928 [No Abstract] [Full Text] [Related]
8. Comparative in vitro activity of norfloxacin against urinary tract pathogens. Haase D; Urias B; Harding G; Ronald A Eur J Clin Microbiol; 1983 Jun; 2(3):235-41. PubMed ID: 6224679 [TBL] [Abstract][Full Text] [Related]
9. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria]. Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920 [TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of pefloxacin compared to other antibiotics. Yourassowsky E; Van der Linden MP; Crokaert F; Glupczynski Y J Antimicrob Chemother; 1986 Apr; 17 Suppl B():19-28. PubMed ID: 3086279 [TBL] [Abstract][Full Text] [Related]
11. [Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1984). III. Secular changes in susceptibility]. Kosakai N; Kumamoto Y; Sakai S; Hirose T; Shigeta S; Shiraiwa Y; Miura Y; Ogata M; Tazaki H; Iri H Jpn J Antibiot; 1986 Nov; 39(11):3019-93. PubMed ID: 3102809 [TBL] [Abstract][Full Text] [Related]
12. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients. Guimaraes MA; Noone P J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708 [TBL] [Abstract][Full Text] [Related]
13. In vitro antibacterial activity of ceftizoxime against gram-negative strains. Debbia E; Soro O Chemioterapia; 1985 Apr; 4(2):166-9. PubMed ID: 3891115 [TBL] [Abstract][Full Text] [Related]
14. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. Barry AL; Jones RN; Thornsberry C; Ayers LW; Gerlach EH; Sommers HM Antimicrob Agents Chemother; 1984 May; 25(5):633-7. PubMed ID: 6233935 [TBL] [Abstract][Full Text] [Related]
15. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution]. Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757 [TBL] [Abstract][Full Text] [Related]
16. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria]. Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T Jpn J Antibiot; 2003 Oct; 56(5):458-96. PubMed ID: 14692381 [TBL] [Abstract][Full Text] [Related]
17. Disk diffusion susceptibility tests with norfloxacin: confirmation of proposed interpretive criteria. Wood SJ; Shadomy S Eur J Clin Microbiol; 1983 Jun; 2(3):242-4. PubMed ID: 6224680 [TBL] [Abstract][Full Text] [Related]
18. In vitro antibacterial activity of norfloxacin and other agents against ocular pathogens. Shungu DL; Tutlane VK; Weinberg E; Gadebusch HH Chemotherapy; 1985; 31(2):112-8. PubMed ID: 3157551 [TBL] [Abstract][Full Text] [Related]
19. [Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1984). I. Susceptibility distribution]. Kosakai N; Kumamoto Y; Sakai S; Hirose T; Shigeta S; Shiraiwa Y; Miura Y; Ogata M; Tazaki H; Iri H Jpn J Antibiot; 1986 Nov; 39(11):2959-3006. PubMed ID: 3102808 [TBL] [Abstract][Full Text] [Related]
20. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). I. Susceptibility distribution]. Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H Jpn J Antibiot; 1995 Nov; 48(11):1627-57. PubMed ID: 8558754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]